National Plan for Epilepsy Act
HB1189, the National Plan for Epilepsy Act, would direct the Secretary of Health and Human Services to create and maintain a national plan to prevent, diagnose, treat, and ultimately cure epilepsy. The bill frames epilepsy as a major public health issue, citing its prevalence, the frequency of uncontrolled seizures, elevated mortality risk, work limitations, and substantial annual health care costs. It also requires the federal government to coordinate epilepsy-related research and services across agencies, improve early diagnosis and care coordination, and support development of better treatments and quality-of-life interventions for people with epilepsy and their caregivers.
The bill establishes a formal federal structure for oversight and coordination, including an Advisory Council on Epilepsy Research, Care, and Services with representatives from federal agencies, clinicians, researchers, people living with epilepsy, caregivers, and nonprofit organizations. The council would meet regularly, hold public meetings, and issue reports to the Secretary and Congress. The Secretary would also be required to submit annual reports evaluating federal epilepsy efforts, recommending priority actions, and describing progress. The plan would include data-sharing requirements across agencies and would sunset on December 31, 2035.
If enacted, the bill would amend the Public Health Service Act by adding a new Section 320C focused on epilepsy programs. It would not create a new benefit program or mandate direct clinical coverage, but it would impose federal planning, reporting, coordination, and advisory requirements on HHS and related agencies, including NIH, CDC, FDA, CMS, HRSA, DOD, and VA. The bill would likely affect federal research priorities, surveillance, interagency coordination, and the visibility of epilepsy as a national health issue, while also requiring data sharing to support annual assessments and reports.
The available context shows no recorded committee debate or votes, so there is no documented opposition or support beyond the bill’s introduction and referral to the House Committee on Energy and Commerce. The bill’s findings and structure suggest a strongly supportive, public-health-oriented approach, emphasizing unmet medical need, caregiver burden, and the need for better coordination and research. Overall, the measure appears to be framed as a consensus-driven effort to improve epilepsy outcomes through federal planning and collaboration.
Because there are no committee transcripts or votes provided, no specific points of contention are documented. Potential areas that could draw scrutiny include the scope of federal coordination, the reporting and data-sharing requirements across agencies, the composition and role of the advisory council, and whether the bill’s planning framework would lead to meaningful action without dedicated funding. The sunset date in 2035 may also be relevant to discussions about whether the program should be temporary or permanent.